MDCX · Medicus Pharma Ltd. · Executive Compensation
$0.16
0.00 (-2.71%)
At close · Sep 14
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“This uncertainty, along with the Company's history of losses, indicates that substantial doubt exists about the Company's ability to continue as a going concern within one year after the date that the financial statements are issued.”View the 10-Q filed Aug 12, 2026
Market Cap
$10.27M
Shares
63.18M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Carolyn Bonner | Chief Financial Officer | Appointed | 2025-12-01 |
| James Quinlan | Chief Financial Officer | Resigned | 2025-12-01 |
| Carolyn Bonner | acting Chief Financial Officer | Appointed | 2025-09-12 |
| Viktoria Slepeniuk | Member of Antev's Board of Directors | Appointed | 2025-09-02 |
| Carolyn Bonner | Member of Antev's Board of Directors | Appointed | 2025-09-02 |
| Faisal Mehmud | Co-Chairman of Antev's Board of Directors | Appointed | 2025-09-02 |
| Paul Marchetto | Co-Chairman of Antev's Board of Directors | Appointed | 2025-09-02 |
| Patrick J. Mahaffy | Member of Medicus's Board of Directors | Appointed | 2025-09-02 |
| Patrick J. Mahaffy | director | Appointed | 2025-09-02 |
| Andrew Smith | Chief Operating Officer | Appointed | 2025-06-23 |